What Researchers Did
Researchers reviewed current scientific literature on how hyperbaric oxygen and other mechanical factors cause acute lung injury, and specifically examined whether exosome-based therapies (tiny biological particles released by cells) could protect the lungs.
What They Found
Hyperbaric oxygen can contribute to acute lung injury by disrupting the air-blood barrier in the lungs, causing uncontrolled inflammation and fluid buildup. In mouse models, exosome preparations significantly reduced lung inflammation and improved vascular stability. However, the review noted that exosome therapies have only been tested in animals and face many barriers before clinical use.
What This Means for Canadian Patients
This review is relevant to Canadian patients receiving high-pressure HBOT or those who have experienced blast, chemical, or mechanical lung injuries. Understanding the lung injury risk from HBOT helps clinicians set appropriate treatment pressures and durations to minimize harm while maximizing benefit.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
This is a narrative review with no original data; exosome therapies discussed are entirely preclinical and years away from clinical application.